Ritu Baral

SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive disorder (MDD). The news immediately propelled Sage's stock, rocketing it past previous highs to $169.58. Cowen thinks there’s still upside. The Rating...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 1 percent on Thursday after the company reported its third consecutive beat and raise earnings report, analysts at Cowen said in a research report. The firm's Ritu Baral,/a> maintains an Outperform rating on Sarepta's stock with an...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) soared higher by more than 25 percent on Tuesday in reaction to the company's announcement that there is now a clear path to approval for its migalastat NDA therapy. Amicus suffered a major setback for its therapy in November, 2016 when the U.S....

Cowen sees positive trends over payor evaluation and re-evaluation of Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Exondys 51, which was approved in last September for the treatment Duchenne Muscular Dystrophy. Encouraging Trends Analyst Ritu Baral noted that checks show that payor discussions...

Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...

Cowen and Company has started the coverage of GlycoMimetics Inc (NASDAQ: GLYC) with an Outperform rating on high confidence of success in the Phase 3 data of Pfizer Inc. (NYSE: PFE)-partnered lead candidate Rivipansel for sickle cell vaso-occlusive crises. "We also think wholly owned GMI-1271 has...

Cowen and Company started coverage on Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating, citing the strong pipeline and the bold steps taken entering into rare disease gene therapy. Analyst Ritu Baral stated the rating was backed by pipeline assets like AT132, AT342 and AT982 and...

Cowen raised its price target on the shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) by $3 to $215 after FDA approved its drug Ocaliva to treat a rare liver disease. "We note the final label is broader than generally expected with responder/non-responder left to clinician discretion...

The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen & Co., led by Ritu Baral, highlighted what...